Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma—An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

(2019) Paolo A. Ascierto et al.   Journal for ImmunoTherapy of Cancer

μPET/CT imaging of local and systemic immune response using 64Cu-αCD11b

(2019) Qizhen Cao et al.   JOURNAL OF NUCLEAR MEDICINE

Expression and significance of Th17 cells and related factors in patients with autoimmune hepatitis

(2019) Jihong An   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy

(2019) Mark Lee et al.   Human Vaccines & Immunotherapeutics

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

(2019) Abdul Rafeh Naqash et al.   Journal for ImmunoTherapy of Cancer

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

(2019) Lars Bastholt et al.   EUROPEAN JOURNAL OF CANCER

An Autocrine Wnt5a Loop Promotes NF-κB Pathway Activation and Cytokine/Chemokine Secretion in Melanoma

(2019) Gastón Barbero et al.   Cells

Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade

(2019) Miriam Möller et al.   JOURNAL OF IMMUNOTHERAPY

Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis

(2019) Claus Steppert et al.   PATHOLOGY & ONCOLOGY RESEARCH

Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma

(2019) Philipp J. Stenzel et al.   Translational Oncology

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Eosinophilic Pneumonias

(2018) James Allen et al.   Journal of Allergy and Clinical Immunology-In Practice

Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model

(2018) Jibin Li et al.   MEDICAL SCIENCE MONITOR

Immune dysregulation in cancer patients developing immune-related adverse events

(2018) Shaheen Khan et al.   BRITISH JOURNAL OF CANCER

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

(2018) Alice Indini et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

(2017) Markus V. Heppt et al.   EUROPEAN JOURNAL OF CANCER

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation

(2017) Jennifer Oyler-Yaniv et al.   MOLECULAR CELL

Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases

(2017) Dilyara Akberova et al.   Journal of Immunology Research

Identifying the Presence of Prostate Cancer in Individuals with PSA Levels

(2017) Georgina Cosma et al.   Frontiers in Immunology

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review

(2017) Eric Peter Thelin et al.   Frontiers in Neurology

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

(2016) P. F. Ferrucci et al.   ANNALS OF ONCOLOGY

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Fragment Length of Circulating Tumor DNA

(2016) Hunter R. Underhill et al.   PLoS Genetics

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

(2013) J. Delyon et al.   ANNALS OF ONCOLOGY

Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study

(2013) Nancy E. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy

(2013) Benjamin Weide et al.   PLoS One

Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer

(2012) Jae Hyuk Lee   ARCHIVES OF SURGERY

Interleukin-6 signaling pathway in targeted therapy for cancer

(2012) Yuqi Guo et al.   CANCER TREATMENT REVIEWS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

(2009) Brendon J Coventry et al.   Journal of Translational Medicine